About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

Details of Drug Reviewed

<table>
<thead>
<tr>
<th>Drug</th>
<th>alogliptin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brand Name</td>
<td>Nesina ™</td>
</tr>
<tr>
<td>Dosage Form(s)</td>
<td>6.25 mg, 12.5 mg and 25 mg oral tablet</td>
</tr>
<tr>
<td>Manufacturer</td>
<td>Takeda Canada Inc.</td>
</tr>
</tbody>
</table>

**Submission Review**

<table>
<thead>
<tr>
<th>Use Reviewed</th>
<th>Type 2 diabetes mellitus (T2DM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug Benefit Council (DBC)</td>
<td>The drug was not reviewed by the DBC.</td>
</tr>
</tbody>
</table>

**Drug Coverage Decision**

<table>
<thead>
<tr>
<th>Date</th>
<th>May 5, 2015</th>
</tr>
</thead>
</table>

**Reason(s)**

Alogliptin was not reviewed by the DBC because it received a “Do not List” recommendation from the CDR. The Ministry of Health reviewed clinical evidence and pharmacoeconomic reports prepared by the CDR, the Canadian Drug Expert Committee (CDEC) Final Recommendation and Reasons, Clinical Practice Reviews from one general physician and two specialists and patient input collected through Your Voice.

- Based on CDR review, the clinical benefit of alogliptin as part of a combination treatment with metformin and a sulfonylurea is uncertain compared to other treatment options.
- Alogliptin is also not approved by Health Canada for use in combination with metformin and a sulfonylurea as is the case with other dipeptidyl peptidase IV (DPP-4) inhibitors.
- Based on the market prices, alogliptin is less costly than sitagliptin and saxagliptin but more costly than linagliptin.

**Other Information**

None
The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the Drug Benefit Council (DBC) gives advice to the Ministry. The DBC looks at:

- advice from a national group called the Common Drug Review
- whether the drug is safe and effective
- whether it is a good value for the people of B.C.
- the ethics of covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a decision based on many factors, including:

- advice from the DBC
- drugs used to treat similar medical conditions that B.C. PharmaCare already covers
- the overall cost of covering the drug

Visit the B.C. Drug Review Process and PharmaCare program for more information.

This document is intended for information only. It does not take the place of advice from a physician or other qualified health care provider.